• Nagy Mekhail, Ramatia Mahboobi, Armin Farajzadeh Deroee, Shrif Costandi, Jarrod Dalton, Maged Guirguis, and Pankaj Mehta.
• Evidence-Based Pain Management Research, Cleveland Clinic, Cleveland, Ohio, U.S.A.; Department of Pain Management, Cleveland Clinic, Cleveland, Ohio, U.S.A.
• Pain Pract. 2014 Apr 1;14(4):301-8.

BackgroundIntrathecal drug delivery (IDD) system with implantable pumps has been used to treat cancer-related pain as well as noncancer-related chronic pain. Opioids, including morphine and hydromorphone, are the most commonly used intrathecal (IT) agents. Although technology, techniques, and knowledge of IDD have improved, dose escalation occurs relatively rapidly in noncancer pain.MethodsRetrospective chart review of IDD pump patients, implanted for a minimum of 2 years, was designed to investigate possible existing predictors that might impact IDD dose escalation, such as patient's demographic risk factors, duration of the treatment, and diagnosis of the patient's pain correlates with increase in medication requirement. Primary outcome was defined as the annual percent escalation in daily opioid dosage, and secondary outcome was the average annual percent reduction in VRS pain scores.ResultsMedian dosage escalation was 17% per year for patients with neuropathic pain compared with 12% per year for patients with other pain modalities. Mean opioid dosage increased 30.4% more rapidly for patients with neuropathic pain than for other pain modalities. The adjusted difference in means was 28.8% (P = 0.001). None of the secondary exposures were statistically significant after the Bonferroni adjustment. No association was found between pain modality and annual percent change in VRS pain score.ConclusionAnnual increases in daily opioid dosage were higher among patients with neuropathic pain than among patients with other modalities; we also found no evidence of difference in annual pain reduction.© 2013 World Institute of Pain.

22 keywords...

hide…